India's largest multispecialty hospital group by bed capacity with pan-India presence and leadership in our three key regions.
We are the only private hospital chain network in India with leadership in three metros (Bengaluru, Kolkata and Pune) with a balanced and diversified presence across metros and non-metros.
Widely recognized brand and network of choice for patients, doctors and healthcare professionals.
Advanced infrastructure and medical equipment, with a strong focus on clinical excellence.
Track record of delivering industry leading growth with strong profitability and efficiency metrics.
Repeatable playbook for integrating and scaling transformative acquisitions to improve access to quality healthcare.
Experienced leadership team with marquee institutional shareholder support.
A substantial number of the company's hospitals is located in Karnataka. Its derived 46.40%, 51.55%, and 59.98%, of the company's revenue from operations in Fiscals 2026, 2025 and 2024, respectively, from its hospitals in Karnataka. Any loss of business or disruption in the operations of these hospitals or geopolitical or policy changes in Karnataka could have a material adverse effect on the company's business, financial condition, results of operations, cash flows and prospects.
The company primarily generates revenue by providing inpatient care at its hospitals. Any inability to maintain or improve the company's admissions and hospital occupancy rates could adversely affect its business, financial condition, results of operations, cash flows and prospects.
The company derived 64.30%, 62.56% and 61.55% of its gross inpatient revenue from cardiac sciences, oncology, neurosciences, gastro sciences, orthopaedics, and renal sciences ("CONGO-R") specialties in Fiscals 2026, 2025 and 2024, respectively, and any negative changes in the demand for these specialties could adversely impact the company's business, results of operations and financial condition.
A portion of the Net Proceeds is proposed to be utilized for repayment or prepayment of certain borrowings in the nature of Non-Convertible Debentures issued by one of the company's Subsidiaries to DBS Bank Ltd., which is the parent company of DBS Bank India Limited, which is deemed to be an "Associate" of Imperius Healthcare Investments Pte. Ltd. (one of its Promoters and Selling Shareholders) in terms of Regulation 21A of SEBI Merchant Bankers Regulations.
Acquisitions, strategic investments, partnerships or alliances may be difficult to identify, acquires and integrate, and may adversely affect the company's business, financial condition, results of operations, cash flows and prospects.
The company is exposed to legal claims and regulatory actions arising from the provision of healthcare services which includes claims arising out of alleged medical negligence by its doctors and other healthcare professionals and may be subject to liabilities arising from operational and equipment-related risks, which could materially and adversely affect the company's reputation, business, financial position, and results of operations. Further, quarantines and sterilizations could limit the operations of hospitals and result in reputational damage.
Any failures to maintain and enhance the company's brand and reputation, and any negative publicity and allegations in the media against its, may adversely affect the level of trust in the company's services and market recognition, which could have an adverse impact on its business, financial condition, results of operations, cash flows and prospects.
The company is required to obtain, renew and maintain statutory and regulatory permits, licenses and accreditations and comply with prescribed quality standards. Any regulatory changes or violations of such rules and regulations, or failures to obtain or renew approvals, licenses, registrations and permits to operates the company's business or comply with prescribed quality standards in a timely manner, or at all, may adversely affect its business, financial condition, results of operations, cash flows and prospects.
The company's operations involve the generation and handling of bio-medical waste and are subject to pollution control laws and regulations. Any failures to comply with applicable bio-medical waste management and pollution control laws and regulations could adversely affect the company's business, results of operations, financial condition and cash flows.
The company derived 49.68%, 49.18% and 49.45% of its gross inpatient revenue from insurance and third-party administrators in Fiscals 2026, 2025 and 2024, respectively. Termination, non-renewal, delay or difficulties in collection or any breach of the conditions of the company's contracts with insurance and third-party administrators, as well as from government and other non-cash payors, could have a material adverse impact on its business, financial condition, results of operations, cash flows and prospects.
